Address
95 Sawyer Road
Waltham, MA 02453
United States of America (the)
Phone
781 652 4500
Website
Sector
Healthcare
Industry
Biotechnology
Employees
4
First IPO Date
August 22, 2017
| Name | Title | Pay | Year Born |
| Manuel Litchman | President, Chief Executive Officer, Interim Chief Financial Officer & Director | 498,263 | 1954 |
| Michael S. Weiss | Executive Chairman | 60,000 | 1966 |
| Robyn Hunter | Corporate Secretary | 0 | 1962 |
| Greg Furrow | Chief Quality Officer | 0 | N/A |
| Peter Carney | Controller & Interim Chief Accounting Officer | 0 | 1987 |
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children’s hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.